Literature DB >> 16940120

In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals.

Maria Souli1, Flora V Kontopidou, Evangelos Koratzanis, Anastasia Antoniadou, Efthimia Giannitsioti, Pinelopi Evangelopoulou, Sofia Kannavaki, Helen Giamarellou.   

Abstract

The in vitro activities of tigecycline and selected antimicrobials were evaluated against a variety of multiple-drug-resistant clinical isolates, including extended-spectrum beta-lactamase- and/or metallo-beta-lactamase-producing gram-negative strains, colistin-resistant strains, vancomycin- and/or linezolid-resistant enterococci, and methicillin-resistant Staphylococcus aureus (MRSA). Tigecycline showed excellent activity against a collection of difficult-to-treat pathogens currently encountered in the hospital setting.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940120      PMCID： PMC1563514          DOI： 10.1128/AAC.00322-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  17 in total

1.  Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase-producing strains of Pseudomonas and Acinetobacter species.

Authors:  K Lee; Y Chong; H B Shin; Y A Kim; D Yong; J H Yum
Journal:  Clin Microbiol Infect       Date:  2001-02       Impact factor: 8.067

2.  Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.

Authors:  Inmaculada A Herrero; Nicolas C Issa; Robin Patel
Journal:  N Engl J Med       Date:  2002-03-14       Impact factor: 91.245

3.  VIM-1 Metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals.

Authors:  P Giakkoupi; A Xanthaki; M Kanelopoulou; A Vlahaki; V Miriagou; S Kontou; E Papafraggas; H Malamou-Lada; L S Tzouvelekis; N J Legakis; A C Vatopoulos
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948

Review 4.  The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.

Authors:  T R Walsh
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

5.  In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.

Authors:  Samuel K Bouchillon; Daryl J Hoban; Brian M Johnson; Tim M Stevens; Michael J Dowzicky; David H Wu; Patricia A Bradford
Journal:  Diagn Microbiol Infect Dis       Date:  2005-04       Impact factor: 2.803

6.  Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.

Authors:  A C Gales; A O Reis; R N Jones
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

7.  Detection of the van alphabet and identification of enterococci and staphylococci at the species level by multiplex PCR.

Authors:  Florence Depardieu; Bruno Perichon; Patrice Courvalin
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

Review 8.  Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control.

Authors:  Enno Stürenburg; Dietrich Mack
Journal:  J Infect       Date:  2003-11       Impact factor: 6.072

9.  First identification of an Escherichia coli clinical isolate producing both metallo-beta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1.

Authors:  I Galani; M Souli; Z Chryssouli; D Katsala; H Giamarellou
Journal:  Clin Microbiol Infect       Date:  2004-08       Impact factor: 8.067

10.  Polymyxin-resistant Acinetobacter spp. isolates: what is next?

Authors:  Adriana O Reis; Deise A M Luz; Maria C B Tognim; Hélio S Sader; Ana C Gales
Journal:  Emerg Infect Dis       Date:  2003-08       Impact factor: 6.883
View more
  17 in total

Review 1.  Global challenge of multidrug-resistant Acinetobacter baumannii.

Authors:  Federico Perez; Andrea M Hujer; Kristine M Hujer; Brooke K Decker; Philip N Rather; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2007-07-23       Impact factor: 5.191

2.  Development of Tyrocidine A analogues with improved antibacterial activity.

Authors:  Michael A Marques; Diane M Citron; Clay C Wang
Journal:  Bioorg Med Chem       Date:  2007-08-11       Impact factor: 3.641

3.  In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group.

Authors:  Luis A Arroyo; Ingeborg Mateos; Verónica González; Javier Aznar
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

4.  Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates?

Authors:  Maria Souli; Panagiota Danai Rekatsina; Zoi Chryssouli; Irene Galani; Helen Giamarellou; Kyriaki Kanellakopoulou
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191

5.  Prevalence of Carbapenemases and Metallo-β-lactamases in Clinical Isolates of Enterobacter Cloacae.

Authors:  Priyanka Banerjee; Tavleen Jaggi; Mehvash Haider; Bibhabati Mishra; Archana Thakur
Journal:  J Clin Diagn Res       Date:  2014-11-20

6.  When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock.

Authors:  Håkan Hanberger; Christian G Giske; Helen Giamarellou
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

7.  Investigation of in-vitro susceptibility of multidrug-resistant Acinetobacter baumannii strains isolated from clinical specimens to tigecycline.

Authors:  Tekin Tas; Esra Kocoglu; Zafer Mengeloglu; Ozlem Bucak; Seyda Karabörk
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

8.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

9.  Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.

Authors:  Karthikeyan K Kumarasamy; Mark A Toleman; Timothy R Walsh; Jay Bagaria; Fafhana Butt; Ravikumar Balakrishnan; Uma Chaudhary; Michel Doumith; Christian G Giske; Seema Irfan; Padma Krishnan; Anil V Kumar; Sunil Maharjan; Shazad Mushtaq; Tabassum Noorie; David L Paterson; Andrew Pearson; Claire Perry; Rachel Pike; Bhargavi Rao; Ujjwayini Ray; Jayanta B Sarma; Madhu Sharma; Elizabeth Sheridan; Mandayam A Thirunarayan; Jane Turton; Supriya Upadhyay; Marina Warner; William Welfare; David M Livermore; Neil Woodford
Journal:  Lancet Infect Dis       Date:  2010-08-10       Impact factor: 25.071

Review 10.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.